Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | RAC1 | P63000 | 4/20 | 0.41 |
| ▸ | PTGDR | Q13258 | 3/20 | 0.40 |
| ▸ | CTSA | P10619 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | DHODH | Q02127 | 2/20 | 0.36 |
| ▸ | RXRA | P19793 | 1/20 | 0.36 |
| ▸ | RXRB | P28702 | 1/20 | 0.36 |
| ▸ | BRAF | P15056 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12070730 | 0.90 | KDM4E (0.40) | KDM4EMAPTALDH1A1RAC1PTGDR | |
| SCHEMBL16499500 | 0.81 | KDM4E (0.49) | KDM4EMAPTALDH1A1RAC1PTGDR | |
| SCHEMBL9985323 | 0.81 | KDM4E (0.53) | KDM4EMAPTALDH1A1RAC1PTGDR | |
| SCHEMBL14927122 | 0.81 | PTPRB (0.38) | MAPTPTGDRCTSARXRARXRB | |
| SCHEMBL12072801 | 0.79 | KDM4E (0.47) | KDM4EMAPTALDH1A1RAC1PTGDR | |
| SCHEMBL9986250 | 0.79 | KDM4E (0.51) | KDM4EMAPTALDH1A1RAC1PTGDR | |
| Carbamic Acid SCHEMBL14916984 | 0.79 | KDM4E (0.41) | KDM4EMAPTALDH1A1RAC1PTGDR | |
| SCHEMBL9985856 | 0.78 | KDM4E (0.52) | KDM4EMAPTALDH1A1RAC1NPC1 | |
| SCHEMBL9984208 | 0.76 | RAC1 (0.64) | KDM4EMAPTALDH1A1RAC1NPC1 | |
| SCHEMBL12070704 | 0.75 | KDM4E (0.49) | KDM4EMAPTALDH1A1RAC1PTGDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8933096-B2 | Antimicrobial agents | Rugers, The State University of New Jersey (US) | 2015-01-13 | — | — | US | disclosed |
| US-20130116278-A1 | ANTIMICROBIAL AGENTS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116278-A1 | ANTIMICROBIAL AGENTS | MRPL21, ARG1, RPP30 | KDM4E 2572/4885MAPT 4783/4885ALDH1A1 3341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.